private:indexpharmaceuticals
|
1498986
|
May 29th, 2019 12:00AM
|
InDex Pharmaceuticals AB
|
346
|
19.00
|
Open
|
Pharmaceuticals
|
May 28th, 2019 10:48PM
|
May 28th, 2019 10:48PM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
Open
|
|
Open
|
Tomtebodavägen 23a
|
Stockholm
|
|
SE
|
171 77
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Mar 26th, 2018 12:00AM
|
InDex Pharmaceuticals AB
|
277
|
16.00
|
Open
|
Pharmaceuticals
|
Mar 26th, 2018 04:54PM
|
Mar 26th, 2018 04:54PM
|
|
Open
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 17th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 16th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 15th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 14th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 13th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 12th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 11th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:indexpharmaceuticals
|
1498986
|
Feb 10th, 2018 12:00AM
|
Index Pharmaceuticals AB
|
249
|
15.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine.
InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm.
|
|
|
|
|
|
|
|
|
|
InDex Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|